TY - JOUR
T1 - Untreated PKU patients without intellectual disability
T2 - What do they teach us?
AU - van Vliet, Danique
AU - van Wegberg, Annemiek M.J.
AU - Ahring, Kirsten
AU - Bik-Multanowski, Miroslaw
AU - Casas, Kari
AU - Didycz, Bozena
AU - Djordjevic, Maja
AU - Hertecant, Jozef L.
AU - Leuzzi, Vincenzo
AU - Mathisen, Per
AU - Nardecchia, Francesca
AU - Powell, Kimberly K.
AU - Rutsch, Frank
AU - Stojiljkovic, Maja
AU - Trefz, Fritz K.
AU - Usurelu, Natalia
AU - Wilson, Callum
AU - van Karnebeek, Clara D.
AU - Hanley, William B.
AU - van Spronsen, Francjan J.
N1 - Publisher Copyright:
© 2019 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2019
Y1 - 2019
N2 - Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.
AB - Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.
KW - Brain vulnerability
KW - Inter-individual differences
KW - Late-treated
KW - Outcome
KW - Phenylketonuria
KW - Untreated
UR - https://www.scopus.com/pages/publications/85074474244
U2 - 10.3390/nu11112572
DO - 10.3390/nu11112572
M3 - Article
C2 - 31731404
AN - SCOPUS:85074474244
SN - 2072-6643
VL - 11
JO - Nutrients
JF - Nutrients
IS - 11
M1 - 2572
ER -